Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders for Acurx Pharmaceuticals, Inc., held on June 17, 2024. The company is an emerging growth company incorporated in Delaware. As of the record date (April 26, 2024), there were 15,823,102 shares of common stock outstanding.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
A quorum was established with 10,648,350 shares represented (approximately 67.29% of outstanding shares). Stockholders voted on two proposals:
- Proposal 1: Election of Directors
- Robert J. DeLuccia: Elected with 5,235,276 votes for; 576,861 withheld.
- Joseph C. Scodari: Elected with 4,807,715 votes for; 1,004,422 withheld.
- James Donohue: Elected with 4,810,817 votes for; 1,001,320 withheld.
- Note: All three nominees received 4,836,213 broker non-votes.
- Proposal 2: Ratification of Independent Auditors
- CohnReznick LLP was ratified for the fiscal year ending December 31, 2024.
- For: 10,542,955 shares
- Against: 69,261 shares
- Abstentions: 36,134 shares
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, risk factors, or contingencies. It strictly reports the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the definitive Proxy Statement filed on April 29, 2024, for detailed biographies of the elected directors and the rationale for the auditor ratification.
- Confirm the total number of shares outstanding (15,823,102) against the most recent 10-Q or 10-K filings to ensure no subsequent issuances have occurred.
- Review the company's upcoming financial reports for the fiscal year ending December 31, 2024, as this 8-K contains no financial performance data.